IVIXF Stock Chart & Stats
$0.04
$0.00(0.00%)
At close: 4:00 PM EDT
$0.04
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.04 - $0.04
Previous CloseN/A
Volume10.00
Average Volume (3M)0.00
Market Cap
$3.51M
Enterprise Value$4.42
Total Cash (Recent Filing)$592.31K
Total Debt (Recent Filing)$1.55M
Price to Earnings (P/E)―
Beta-3.82
Next Earnings
Feb 24, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding109,200,640
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.59
Price to Sales (P/S)8.17
P/FCF Ratio-1.32
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Targeted PDT PlatformThe IVX-P02 platform is designed around a targeted photodynamic therapy approach, giving Invion a defined technology base rather than a broad, unfocused research effort. If development succeeds, this mechanism could support differentiated oncology applications and broader product potential.
Focused Oncology PipelineInvion is concentrating its limited resources on specific oncology indications while progressing its candidate toward clinical development and possible partnering. This focused strategy can improve capital allocation and create a pathway to commercial scale beyond the company’s small internal operating base.
Moderate Reported LeverageReported debt is moderate relative to shareholders’ equity, so leverage is not identified as the primary balance-sheet pressure. This provides some structural financial flexibility compared with a highly debt-funded biotech, although continued losses remain important to the company’s overall funding position.
Bears Say
Persistent UnprofitabilityRecurring operating and net losses show that Invion has not yet established a profitable commercial model. Revenue also fell from approximately 3.3–4.1M in 2022–2024 to near zero in 2025 and only about 0.4M in 2026, weakening the foundation for self-funded growth.
Sustained Cash BurnNegative operating and free cash flow indicate that Invion continues to consume cash to fund its activities rather than finance operations internally. Sustained outflows can increase reliance on future capital raising or partnerships and may constrain the pace of therapeutic development over coming quarters.
Severe Equity ErosionThe sharp reduction in equity is consistent with ongoing losses and the consumption of shareholder capital. A smaller equity base leaves less balance-sheet capacity to absorb further development spending, increases dependence on external funding, and can weaken investors’ long-term financial protection.
Invion News
IVIXF FAQ
What was Invion’s price range in the past 12 months?
Invion lowest stock price was $0.04 and its highest was $0.04 in the past 12 months.
What is Invion’s market cap?
Invion’s market cap is $3.51M.
When is Invion’s upcoming earnings report date?
Invion’s upcoming earnings report date is Feb 24, 2027 which is in 162 days.
How were Invion’s earnings last quarter?
Invion released its earnings results on Aug 27, 2026. The company reported -$0.015 earnings per share for the quarter.
Is Invion overvalued?
According to Wall Street analysts Invion’s price is currently Overvalued.
Does Invion pay dividends?
Invion does not currently pay dividends.
What is Invion’s EPS estimate?
Invion’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Invion have?
Invion has 109,200,640 shares outstanding.
What happened to Invion’s price movement after its last earnings report?
Invion reported an EPS of -$0.015 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Invion?
Currently, no hedge funds are holding shares in IVIXF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Invion Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
0.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-9.02%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Invion
Invion Limited, an Australian clinical-stage life sciences enterprise, is actively engaged in the research and development of photodynamic therapy (PDT) to address various cancer types. Its flagship offering, IVX-PDT, is a photosensitizer agent being developed to combat skin cancers alongside a range of solid tumors, including those affecting the lungs, prostate, ovaries, and mesothelioma. The company has forged a research and development alliance with the Hudson Institute of Medical Research, jointly pursuing R&D initiatives for its Photosoft technology across a broad spectrum of cancer treatments. Moreover, a dedicated research agreement with the Peter MacCallum Cancer Centre facilitates pre-clinical and in-vitro investigations into Invion's IVX-PDT for ano-genital cancers, such as penile and anal cancers. The firm was established in 2000 and is headquartered in Melbourne, Australia.
Technical Analysis
Percheron Therapeutics
―
Argent Biopharma
―
Medical Developments International Limited
―
Althea Group Holdings Ltd.
―
IDT Australia Limited
―